Kemadrin (Procyclidine Hydrochloride)

Procyclidine works by competitively blocking muscarinic acetylcholine receptors in the basal ganglia. This antagonism reduces excessive cholinergic activity, allowing dopamine pathways to function more effectively and improving motor control in Parkinsonian and drug‑induced movement disorders.

The appropriate dose of Kemadrin is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, renal function, and response to therapy. Dosage adjustments are made to achieve optimal symptom control while minimizing side effects.

The safety of Kemadrin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified prescriber.

To order Kemadrin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kemadrin (Procyclidine) is similar to other anticholinergics such as benztropine and trihexyphenidyl in its mechanism of blocking muscarinic receptors. Differences may lie in potency, duration of action, and individual side‑effect profiles, which influence a prescriber’s choice based on patient tolerance and therapeutic response.

Kemadrin tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Kemadrin is taken orally as a tablet, usually with a glass of water. The exact timing (e.g., with meals or on an empty stomach) and frequency are directed by the prescribing clinician to align with the patient’s therapeutic plan.

Serious risks include confusion, hallucinations, severe tachycardia, acute glaucoma exacerbation, and rare occurrences of neuroleptic malignant syndrome. Patients should be monitored closely for any sudden changes in mental status or cardiovascular symptoms, and medical attention should be sought promptly if they arise.

Kemadrin is contraindicated in patients with known hypersensitivity to Procyclidine or any tablet excipients, those with uncontrolled narrow‑angle glaucoma, and individuals with severe urinary retention or gastrointestinal obstruction. Caution is also advised for patients with significant cardiac disease or renal impairment.